Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 526 to 540 of 2854 results for process

  1. Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]

    Awaiting development Reference number: GID-TA11961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Giredestrant for adjuvant treatment of oestrogen-receptor positive HER2-negative early breast cancer [TSID12400]

    Awaiting development Reference number: GID-TA12031 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743]

    Awaiting development Reference number: GID-TA11969 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia

    Awaiting development Reference number: GID-HTG10678 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  6. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development Reference number: GID-TA10700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Early value assessment interim statement (PMG39)

    This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need

  9. CM-AT for behaviours associated with autism in children and young people [ID6731]

    Awaiting development Reference number: GID-TA11955 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Xanomeline tartrate–trospium chloride for treating schizophrenia [ID6716]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Upadacitinib for treating moderately to severely active systemic lupus erythematosus [TSID12366]

    Awaiting development Reference number: GID-TA12021 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Admilparant for treating idiopathic pulmonary fibrosis [TSID12393]

    Awaiting development Reference number: GID-TA12004 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Selinexor for maintenance treatment of p53 wild-type advanced or recurrent endometrial cancer after systemic treatment [TSID12374]

    Awaiting development Reference number: GID-TA12014 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [TSID12377]

    Awaiting development Reference number: GID-TA12000 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Povorcitinib for treating non-segmental vitiligo [TSID12388]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development